https://doi.org/10.4081/btvb.2024.114
Location of metastasis and complications in patients with venous thromboembolism and cancer: systematic review
Submitted: 15 January 2024
Accepted: 5 April 2024
Published: 16 May 2024
Accepted: 5 April 2024
Abstract Views: 259
PDF: 95
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
According to current guidelines, patients with venous thromboembolism (VTE) and active cancer should receive prolonged anticoagulant treatment (>6 months). In patients with cancer-associated thrombosis (CAT), metastasis is a factor in recurrent VTE and bleeding; however, the function of metastasis location remains unclear. In order to assess the risk of complications (such as bleeding or recurrent VTE) based on the location of metastases in patients with CAT, we conducted a systematic review. The PubMed database search was used to perform a systematic review. MESH terms pertaining to metastasis, VTE, and neoplasms were employed. Patients with CAT who were at least eighteen years old and receiving therapeutic doses of anticoagulants were included, as were details regarding the locations of metastases and the availability of patients who had complications (bleeding or recurrent VTE). Among the 1,447 articles found by the search, 7 retrospective studies met all eligibility requirements and were added to the analysis. The majority of these studies addressed brain metastases. Studies found that intracranial hemorrhage occurred between 4% and 19% of the time. In the context of brain metastases and VTE, other studies examined the safety and effectiveness of direct oral anticoagulants in comparison to low-molecular-weight heparin. This systematic review draws attention to the paucity of data regarding the impact of metastasis location on complications in CAT patients. Further research is required to assess the effect of metastasis location on the risk of VTE complications in patients with CAT.
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712-23.
DOI: https://doi.org/10.1182/blood-2013-04-460121
Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res 2007;120:S41-S50.
DOI: https://doi.org/10.1016/S0049-3848(07)70129-9
Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
DOI: https://doi.org/10.1182/blood-2002-01-0108
Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020;38:496-520.
DOI: https://doi.org/10.1200/JCO.19.01461
Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23:e334-e347.
Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 2020;22:171-86.
DOI: https://doi.org/10.1007/s12094-019-02263-z
Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol Off J Eur Soc Med Oncol 2023;34:452-67.
DOI: https://doi.org/10.1016/j.annonc.2022.12.014
Louzada ML, Majeed H, Dao V, Wells PS. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: A systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 2011;22:86-91.
DOI: https://doi.org/10.1097/MBC.0b013e328341f030
Lee AYY, Levine MN, Baker RI, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer 2003;349:146-53.
DOI: https://doi.org/10.1056/NEJMoa025313
Woodruff S, Lee AYY, Carrier M, Feugère G, Abreu P, Heissler J. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. J Thromb Thrombolysis 2019;47:495.
DOI: https://doi.org/10.1007/s11239-019-01833-w
Monreal M, Falgá C, Valdés M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE registry. J Thromb Haemost 2006;4:1950-6.
DOI: https://doi.org/10.1111/j.1538-7836.2006.02082.x
Verso M, Agnelli G, Munoz A, et al. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer 2022;165:136-45.
DOI: https://doi.org/10.1016/j.ejca.2022.01.023
Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1891-4.
DOI: https://doi.org/10.1111/jth.14219
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119-26.
DOI: https://doi.org/10.1111/jth.13140
Schiff D, DeAngelis L. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994:493-8.
DOI: https://doi.org/10.1002/1097-0142(19940115)73:2<493::AID-CNCR2820730240>3.0.CO;2-D
Alvarado G, Noor R, Bassett R, et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 2012;22:310.
DOI: https://doi.org/10.1097/CMR.0b013e328353efd8
Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 2015;126: 494-9.
DOI: https://doi.org/10.1182/blood-2015-02-626788
Chai-Adisaksopha C, Linkins LA, Alkindi SY, et al. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost 2017;117:589-94.
DOI: https://doi.org/10.1160/TH16-09-0680
Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019;17:72-6.
DOI: https://doi.org/10.1111/jth.14336
Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv 2020;4:6291-7.
DOI: https://doi.org/10.1182/bloodadvances.2020003238
Lee A, Oley F, Lo M, et al. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res 2021;208:148-55.
DOI: https://doi.org/10.1016/j.thromres.2021.10.023
Hunter BD, Minichiello T, Bent S. Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review. J Thromb Thrombolysis 2017;44:392-8.
DOI: https://doi.org/10.1007/s11239-017-1536-7
Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016;14: 1736-40.
DOI: https://doi.org/10.1111/jth.13387
Giustozzi M, Proietti G, Becattini C, et al. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022;6:4873.
DOI: https://doi.org/10.1182/bloodadvances.2022008086
Cohen AT, Wallenhorst C, Choudhuri S, et al. A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer. Thromb Haemost 2023.
DOI: https://doi.org/10.1055/a-2145-7238
Barca-Hernando M, Lopez-Ruz S, Marin-Romero S, et al. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy. Res Pract Thromb Haemost 2023;7.
DOI: https://doi.org/10.1016/j.rpth.2023.100115
Rice DB, Kloda LA, Levis B, et al. Are MEDLINE searches sufficient for systematic reviews and meta-analyses of the diagnostic accuracy of depression screening tools? A review of meta-analyses. J Psychosom Res 2016;87:7-13.
DOI: https://doi.org/10.1016/j.jpsychores.2016.06.002
Van Enst WA, Scholten RJPM, Whiting P, et al. Meta-epidemiologic analysis indicates that MEDLINE searches are sufficient for diagnostic test accuracy systematic reviews. J Clin Epidemiol 2014;67:1192-9.
DOI: https://doi.org/10.1016/j.jclinepi.2014.05.008
Mohammed KA, Hinyard L, Schoen MW, et al. Description of Venous Thromboembolism in Hospitalized Patients With Metastatic Cancer: A National Sample. J Natl Compr Canc Netw 2018;16:136-43.
DOI: https://doi.org/10.6004/jnccn.2017.7037
Conteduca V, Scarpi E, Wetterskog D, et al. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer 2022;150:1166-73.
DOI: https://doi.org/10.1002/ijc.33834
How to Cite
Barca-Hernando, M., Garcia-Garcia, V., & Jara-Palomares, L. (2024). Location of metastasis and complications in patients with venous thromboembolism and cancer: systematic review. Bleeding, Thrombosis and Vascular Biology, 3(s1). https://doi.org/10.4081/btvb.2024.114
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
